Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03889444 · ClinicalTrials.gov registry record
Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 141
- Enrollment target
NCT03889444 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 141 participants.
The verdict
NCT03889444 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 141 participants
- Enrollment target
Study Summary
A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.
Interventions
- DRUG Dexamethasone intravitreal implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2019-06-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03889444
The ClinicalTrials.gov registry entry for NCT03889444 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexamethasone intravitreal implant is the first listed.
NCT03889444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03889444 about?
NCT03889444 is a clinical study titled "Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)". A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.
What is the current status of trial NCT03889444?
This trial is currently completed. The enrollment target is 141 participants. The study started on 2019-01-15. Estimated completion is 2019-06-07.
What interventions are being tested in trial NCT03889444?
The interventions under investigation include: Dexamethasone intravitreal implant (DRUG).
Who is sponsoring clinical trial NCT03889444?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.